Alfredo Molteni

ORCID: 0000-0001-5380-1483 · 3 papers in corpus · active 2018-2023

Study types

  • article 3

Condition tags

  • endometriosis 1
article 2023
·doi:10.1097/hs9.0000000000000867

Severe thrombocytopenia is a relatively uncommon event in myelodysplastic syndromes (MDS) and may occur in high-risk patients, advocating treatment with hypomethylating agents or with allogeneic bone marrow transplantation.1 In low-risk pat…

article 2022
·doi:10.1182/blood-2022-157430

Thrombocytopenia affects about two thirds of patients with myelodysplastic syndromes (MDS) and treatment is not standardized. Immunosuppressants, such as corticosteroids, cyclosporin or anti-thymocyte globulin show some efficacy, particular…

article 2018
·doi:10.1182/blood-2018-99-115283

Abstract Background: Severe thrombocytopenia is an uncommon event in patients (pts) with lower-risk MDS, but it may significantly affect the prognosis. No specific pharmacological approaches other than hypometilating agents (not licensed in…